Qianji Capital

Dr. Wu Jun, the founder and chairman, leads investment strategy. Xu Qing, managing partner, and Zhang Min, managing director, are named operating leaders. The firm's decision-making structure is not publicly detailed, but public record shows Dr. Wu as the central figure.

Qianji sources primarily through co-investor partnerships rather than a fully proprietary funnel. The firm's recurring relationship with Shunwei Capital and Fidelity Asia suggests a collaborative sourcing model where it accesses deals originated by larger institutional partners, particularly in healthcare.

Co-investment is central to Qianji's strategy. The firm has invested alongside Fidelity Asia (Eight Roads) in TreeENT Health and Shunwei Capital across healthcare rounds. Rather than leading rounds, Qianji typically participates as a syndicate partner.

Healthcare is a core vertical — demonstrated by positions like TreeENT Health — but Qianji is a generalist asset manager. Its strategy also spans enterprise software and broader technology investments, with a balanced mandate across public and private markets.

Changsha, in Hunan province, positions Qianji within China's central-southern economic corridor. This region has developed its own concentration of healthcare and industrial-tech companies. Operating outside the top-tier hubs likely gives Qianji differentiated access to mid-market deals with less institutional competition.

Qianji is classified as an asset manager, not a family office, and sources describe it as an investment company. The specific LP base is not publicly disclosed, but the presence of named managing partners suggests a multi-client or institutional structure rather than a single-family vehicle.

Qianji invests primarily across China. The firm's deal activity reflects an onshore mandate, with no public indication of cross-border investments. Its Changsha base provides a regional anchor for sourcing within China's central provinces.